ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Core Viewpoint - ImmunityBio, Inc. has secured $75 million in non-dilutive financing, increasing total committed capital under its Royalty Interest Purchase Agreement to $375 million [1] Financing Details - The financing is part of an existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital [1] - The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while keeping the royalty cap unchanged [1]